{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06431594",
            "orgStudyIdInfo": {
                "id": "222730"
            },
            "secondaryIdInfos": [
                {
                    "id": "2024-513860-25",
                    "type": "OTHER",
                    "domain": "EU CT Number"
                }
            ],
            "organization": {
                "fullName": "GlaxoSmithKline",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors",
            "officialTitle": "A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Subjects With Advanced Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-to-evaluate-the-safety-tolerability-pharmacokinetics-and-clinical-activity-of-for-injection-in-participants-with-advanced-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-06-21",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-10-15",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-01-21",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-05-21",
            "studyFirstSubmitQcDate": "2024-05-22",
            "studyFirstPostDateStruct": {
                "date": "2024-05-28",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-18",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-21",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "GlaxoSmithKline",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "The goal of this study is to assess the safety and tolerability of GSK5733584. The study will also see how the levels of GSK5733584 change over time at different dose amount."
        },
        "conditionsModule": {
            "conditions": [
                "Solid Tumors"
            ],
            "keywords": [
                "Solid Tumors",
                "GSK5733584"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 240,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part 1: Dose Escalation",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: GSK5733584"
                    ]
                },
                {
                    "label": "Part 2: Dose Expansion",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: GSK5733584"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "GSK5733584",
                    "description": "GSK5733584 will be administered",
                    "armGroupLabels": [
                        "Part 1: Dose Escalation",
                        "Part 2: Dose Expansion"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Part 1: Number of participants with dose limiting toxicity (DLT)",
                    "timeFrame": "Up to 21 days"
                },
                {
                    "measure": "Part 2: Objective Response Rate (ORR)",
                    "description": "ORR is defined as the proportion of participants with at least one confirmed Complete Response (CR) or Partial Response (PR) as defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1)",
                    "timeFrame": "Up to approximately 28 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Part 1 and 2: Maximum observed concentration (Cmax) of GSK5733584",
                    "timeFrame": "Up to approximately 31 months"
                },
                {
                    "measure": "Part 1 and 2: Time to reach Cmax (Tmax) of GSK5733584",
                    "timeFrame": "Up to approximately 31 months"
                },
                {
                    "measure": "Part 1 and 2: Area under the concentration-time curve (AUC) of GSK5733584",
                    "timeFrame": "Up to approximately 31 months"
                },
                {
                    "measure": "Part 1: Objective Response Rate (ORR)",
                    "description": "ORR is defined as the proportion of participants with at least one confirmed CR or PR as defined by RECIST 1.1",
                    "timeFrame": "Up to approximately 31 months"
                },
                {
                    "measure": "Part 1 and 2: Disease control rate (DCR)",
                    "description": "DCR is defined as the percentage of subjects whose best overall response is Complete Response (CR), Partial Response (PR) or Stable Disease (SD)",
                    "timeFrame": "Up to approximately 31 months"
                },
                {
                    "measure": "Part 1 and 2: Duration of response (DoR)",
                    "description": "DoR is defined as the time interval between the date of the first documented response (CR or PR) and the date of the first documented disease progression or death due to any cause",
                    "timeFrame": "Up to approximately 31 months"
                },
                {
                    "measure": "Part 1 and 2: Progression-free survival (PFS)",
                    "description": "PFS is defined as the time interval between randomization (or from the first dose of the intervention) and the first documented disease progression or death due to any cause (whichever occurs first).",
                    "timeFrame": "Up to approximately 31 months"
                },
                {
                    "measure": "Part 1 and 2:Number of participants with treatment-emergent Anti-drug antibodies (ADA)",
                    "timeFrame": "Up to approximately 31 months"
                },
                {
                    "measure": "Part 1 and 2: Titers of ADA to GSK5733584",
                    "timeFrame": "Up to approximately 31 months"
                },
                {
                    "measure": "Part 1 and 2: Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)",
                    "timeFrame": "Up to approximately 31 months"
                },
                {
                    "measure": "Part 1 and 2: Number of participants with clinically significant changes in physical examination",
                    "timeFrame": "Baseline (Day -1) and up to approximately 31 months"
                },
                {
                    "measure": "Part 1 and 2: Change from baseline in body temperature (degree Celsius)",
                    "timeFrame": "Baseline (Day -1) and up to approximately 31 months"
                },
                {
                    "measure": "Part 1 and 2: Change from baseline in respiratory rate (breaths per minute)",
                    "timeFrame": "Baseline (Day -1) and up to approximately 31 months"
                },
                {
                    "measure": "Part 1 and 2: Change from baseline in pulse rate (beats per minute)",
                    "timeFrame": "Baseline (Day -1) and up to approximately 31 months"
                },
                {
                    "measure": "Part 1 and 2: Change from baseline in blood pressure [millimetres of mercury (mmHg)]",
                    "timeFrame": "Baseline (Day -1) and up to approximately 31 months"
                },
                {
                    "measure": "Part 1 and 2: Change from baseline in weight [kilogram (kg)]",
                    "timeFrame": "Baseline (Day -1) and up to approximately 31 months"
                },
                {
                    "measure": "Part 1 and 2: Change from baseline in white blood cell count (cells per microliter)",
                    "timeFrame": "Baseline (Day -1) and up to approximately 31 months"
                },
                {
                    "measure": "Part 1 and 2: Change from baseline in hemoglobin (grams per deciliter)",
                    "timeFrame": "Baseline (Day -1) and up to approximately 31 months"
                },
                {
                    "measure": "Part 1 and 2: Change from Baseline in Platelet count (cells per microliter)",
                    "timeFrame": "Baseline (Day -1) and up to approximately 31 months"
                },
                {
                    "measure": "Part 1 and 2: Change from Baseline in Red Blood Cell Count (RBC) (million cells per microliter)",
                    "timeFrame": "Baseline (Day -1) and up to approximately 31 months"
                },
                {
                    "measure": "Part 1 and 2: Change from Baseline in haematocrit (Proportion of red blood cells in blood)",
                    "timeFrame": "Baseline (Day -1) and up to approximately 31 months"
                },
                {
                    "measure": "Part 1 and 2: Change from Baseline in Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils (giga cells per litre)",
                    "timeFrame": "Baseline (Day -1) and up to approximately 31 months"
                },
                {
                    "measure": "Part 1 and 2: Change from Baseline in Glucose (fasting), Blood Urea Nitrogen (BUN), Creatinine, Sodium, Potassium, Calcium, Chloride, Magnesium Direct Bilirubin and Total Bilirubin (milligrams per decilitre)",
                    "timeFrame": "Baseline (Day -1) and up to approximately 31 months"
                },
                {
                    "measure": "Part 1 and 2: Change from Baseline in AST/SGOT, ALT/ SGPT, ALP and CPK (International Units per litre)",
                    "description": "Aspartate Aminotransferase (AST) / Serum Glutamic-Oxaloacetic Transaminase (SGOT), Alanine Aminotransferase (ALT)/ Serum Glutamic-Pyruvic Transaminase and (SGPT), Alkaline phosphatase (ALP) and Creatinine Phosphokinase (CPK) will be analysed",
                    "timeFrame": "Baseline (Day -1) and up to approximately 31 months"
                },
                {
                    "measure": "Part 1 and 2: Change from baseline in Total Protein and Albumin (Grams per deciliter)",
                    "timeFrame": "Baseline (Day -1) and up to approximately 31 months"
                },
                {
                    "measure": "Part 1 and 2: Change from baseline in Amylase and Lipase (Units per liter)",
                    "timeFrame": "Baseline (Day -1) and up to approximately 31 months"
                },
                {
                    "measure": "Part 1 and 2: Change from baseline in Creatinine clearance (milliliter per minute)",
                    "timeFrame": "Baseline (Day -1) and up to approximately 31 months"
                },
                {
                    "measure": "Part 1 and 2: Change from baseline in Activated Partial Thromboplastin Time (aPTT), Prothrombin Time (PT) and Thrombin time (seconds)",
                    "timeFrame": "Baseline (Day -1) and up to approximately 31 months"
                },
                {
                    "measure": "Part 1 and 2: Change from baseline in fibrinogen (milligrams per deciliter)",
                    "timeFrame": "Baseline (Day -1) and up to approximately 31 months"
                },
                {
                    "measure": "Part 1 and 2: Change from baseline in liver panel parameter: International Normalized Ratio (INR)",
                    "timeFrame": "Baseline (Day -1) and up to approximately 31 months"
                },
                {
                    "measure": "Part 1 and 2: Change from baseline in routine urine tests: Leukocyte esterase",
                    "description": "Leukocyte esterase measured as negative or positive",
                    "timeFrame": "Baseline (Day -1) and up to approximately 31 months"
                },
                {
                    "measure": "Part 1 and 2: Change from baseline in routine urine tests: Occult blood (10^9 Cells Per Liter)",
                    "timeFrame": "Baseline (Day -1) and up to approximately 31 months"
                },
                {
                    "measure": "Part 1 and 2: Change from baseline in routine urine tests: potential of hydrogen (pH) value",
                    "timeFrame": "Baseline (Day -1) and up to approximately 31 months"
                },
                {
                    "measure": "Part 1 and 2: Change from baseline in routine urine tests: Protein and bilirubin (Grams Per Liter)",
                    "timeFrame": "Baseline (Day -1) and up to approximately 31 months"
                },
                {
                    "measure": "Part 1 and 2: Change From Baseline in routine urine tests: Specific Gravity (Ratio)",
                    "timeFrame": "Baseline (Day -1) and up to approximately 31 months"
                },
                {
                    "measure": "Part 1 and 2: Change from baseline in CA-125 tumor marker [units per milliliter (U/mL)]",
                    "timeFrame": "Baseline (Day -1) and up to approximately 31 months"
                },
                {
                    "measure": "Part 1 and 2: Change from baseline in Electrocardiogram (ECG) readings [milliseconds (msec)]",
                    "timeFrame": "Baseline (Day -1) and up to approximately 31 months"
                },
                {
                    "measure": "Part 1 and 2: Change from baseline in Left ventricular ejection fraction (LVEF) [Percentage]",
                    "timeFrame": "Baseline (Day -1) and up to approximately 31 months"
                },
                {
                    "measure": "Part 1 and 2: Change from baseline in Eastern Cooperative Oncology Group Performance Scale (ECOG PS) score",
                    "description": "ECOG PS is used for measuring how the disease impacts a patient's daily living abilities. The grades for the scale range from 0 (fully active) to 5 (dead), with increasing severity.",
                    "timeFrame": "Baseline (Day -1) and up to approximately 31 months"
                },
                {
                    "measure": "Part 2: Overall Survival (OS)",
                    "description": "OS is defined as the time interval between the date of randomization (or from the first dose of the investigational product) and the date of death due to any cause",
                    "timeFrame": "Up to approximately 31 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Males or females aged 18 years or older (\u226518 years).\n* Participants with pathologically confirmed advanced solid tumor (who have failed or are intolerant to standard of care).\n* Participants have at least one target lesion as assessed per the RECIST 1.1\n* Tumor tissue from a newly obtained biopsy or archival tumor tissue is required for retrospective detection of B7 homolog 4 (B7-H4) expression by Immunohistochemistry (IHC) in central laboratory and other biomarker analysis. Tissue from a newly obtained biopsy is preferred. If a newly obtained biopsy is not feasible, archival tumor tissue within 2 years prior to the first dose of study drug is acceptable.\n* Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 to 2 and no deterioration within 2 weeks before the first dose.\n* Have a life expectancy of at least 12 weeks.\n\nExclusion Criteria:\n\n* Have received any of B7-H4-targeted therapies.\n* Have received any of cytotoxic chemotherapy drugs, anti-tumor traditional Chinese medicines or other anti-tumor drugs within 28 days prior to the first dose of study drug; or need to continue these drugs during the study.\n* Have received locoregional radiation therapy within 2 weeks prior to the first dose of study drug; more than 30% of bone marrow irradiation or wide-field radiation therapy within 4 weeks prior to the first dose of study treatment.\n* Presence of pleural/abdominal effusion/ascites requiring clinical intervention; presence of pericardial effusion\n* Major surgery within 4 weeks prior to the first dose of study treatment.\n* Evidence of brain metastasis unless asymptomatic.\n* Has inadequate bone marrow reserve or hepatic/renal functions.\n* Mean Fridericia-corrected QT interval (QTcF) \\> 470 millisecond (msec) on resting ECG.\n* Evidence of current clinically significant arrhythmias or ECG abnormalities\n* Risk factors of prolonged QTc or arrhythmia events,\n* Left ventricular ejection fraction (LVEF) \\< 50%.\n* Have severe, uncontrolled or active cardiovascular disorders, serious or poorly controlled hypertension, clinically significant bleeding symptoms or serious arteriovenous thromboembolic events\n* Any evidence of current Interstitial lung disease (ILD) or pneumonitis or a prior history of ILD or pneumonitis requiring high-dose systemic glucocorticoids.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "US GSK Clinical Trials Call Center",
                    "role": "CONTACT",
                    "phone": "877-379-3718",
                    "email": "GSKClinicalSupportHD@gsk.com"
                },
                {
                    "name": "EU GSK Clinical Trials Call Center",
                    "role": "CONTACT",
                    "phone": "+44 (0) 20 89904466",
                    "email": "GSKClinicalSupportHD@gsk.com"
                }
            ],
            "locations": [
                {
                    "facility": "GSK Investigational Site",
                    "city": "Lake Mary",
                    "state": "Florida",
                    "zip": "32746",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Alexander Philipovskiy",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 28.75888,
                        "lon": -81.31784
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02114",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Sara Bouberhan",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02215",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Antonio Giordano",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "city": "Detroit",
                    "state": "Michigan",
                    "zip": "48201",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Ira Winer",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.33143,
                        "lon": -83.04575
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75230",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Minal Barve",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "city": "West Valley City",
                    "state": "Utah",
                    "zip": "84119",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "William McKean",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.69161,
                        "lon": -112.00105
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "city": "Seattle",
                    "state": "Washington",
                    "zip": "98109-1023",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Kalyan Banda",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 47.60621,
                        "lon": -122.33207
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "city": "Blacktown",
                    "state": "New South Wales",
                    "zip": "2148",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Phuong Dinh",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -33.76667,
                        "lon": 150.91667
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "city": "Sydney",
                    "state": "New South Wales",
                    "zip": "2109",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Dhanusha Sabanathan",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -33.86785,
                        "lon": 151.20732
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "city": "Ottawa",
                    "state": "Ontario",
                    "zip": "K1H 8L6",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Moira Katherine Rushton-Marovac",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 45.41117,
                        "lon": -75.69812
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "city": "Toronto",
                    "state": "Ontario",
                    "zip": "M5G 2M9",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Philippe Bedard",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.70011,
                        "lon": -79.4163
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "city": "Montr\u00e9al",
                    "state": "Quebec",
                    "zip": "H2X 0A9",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Diane Provencher",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 45.50884,
                        "lon": -73.58781
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "city": "Helsinki",
                    "zip": "00290",
                    "country": "Finland",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Katriina Jalkanen",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 60.16952,
                        "lon": 24.93545
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "city": "Amsterdam",
                    "zip": "1066 CX",
                    "country": "Netherlands",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Neeltje Steeghs",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 52.37403,
                        "lon": 4.88969
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP",
                "ICF",
                "CSR"
            ],
            "timeFrame": "Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.",
            "accessCriteria": "Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.",
            "url": "https://www.gsk.com/en-gb/innovation/trials/data-transparency/"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ]
        }
    },
    "hasResults": false
}